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Abstract
Aims/hypothesis Long-term exposure to NEFAs leads to
inhibition of glucose-induced insulin secretion. We tested
whether the release of somatostatin and glucagon, the two
other major islet hormones, is also affected.
Methods Mouse pancreatic islets were cultured for 72 h at
4.5 or 15 mmol/l glucose with or without 0.5 mmol/l oleate
or palmitate. The release of glucagon and somatostatin
during subsequent 1 h incubations at 1 or 20 mmol/l glucose
as well as the islet content of the two hormones were
determined. Lipid-induced changes in islet cell ultrastruc-
ture were assessed by electron microscopy.
Results Cultureat15mmol/l glucose increasedislet glucagon
content by ∼50% relative to that observed following culture at
4.5 mmol/l glucose. Inclusion of oleate or palmitate reduced
islet glucagon content by 25% (at 4.5 mmol/l glucose) to 50%
(at 15 mmol/l glucose). Long-term exposure to the NEFA
increased glucagon secretion at 1 mmol/l glucose by 50%
(when islets had been cultured at 15 mmol/l glucose) to 100%
(with 4.5 mmol/l glucose in the culture medium) and
abolished the inhibitory effect of 20 mmol/l glucose on
glucagon secretion. Somatostatin content was unaffected by
glucoseandlipids,butglucose-inducedsomatostatinsecretion
was reduced by ∼50% following long-term exposure to either
of the NEFA, regardless of whether the culture medium
contained 4.5 or 15 mmol/l glucose. Ultrastructural evidence
of lipid deposition was seen in <10% of non-beta cells but in
>80% of the beta cells.
Conclusions/interpretation Long-term exposure to high
glucose and/or NEFA affects the release of somatostatin
and glucagon. The effects on glucagon secretion are very
pronounced and in type 2 diabetes in vivo may aggravate
the hyperglycaemic effects due to lack of insulin.
Keywords Diabetes.Glucagon.Glucolipotoxicity.
NEFA.Oleate.Palmitate.Somatostatin
Abbreviation
CICR Ca
2+-induced Ca
2+ release
Introduction
Obesity results in increased release of fatty acids from the
adipocytes and thereby elevates circulating levels of NEFA.
NEFA in turn affect insulin secretion and action. The
effects of NEFA differ depending on the length of exposure.
Short-term exposure (∼1 h) to lipids stimulates glucagon
and insulin secretion, but inhibits somatostatin release [1].
Following long-term (72 h) exposure, however, glucose-
induced insulin secretion is strongly reduced [2]. Recently,
we reported that palmitate and oleate reduced glucose-
evoked insulin secretion by ∼80%, while not affecting
exocytosis of the secretory granules as monitored by
capacitance measurements [3]. We therefore proposed that
lipid pre-treatment somehow interferes with the emptying
of insulin from the secretory granules [3]. Here we have
analysed glucagon and somatostatin secretion in mouse
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(4.5 mmol/l) or high (15 mmol/l) glucose for 72 h. We
demonstrate that the suppression of insulin secretion is
associated with hypersecretion of glucagon and a reduction
of glucose-stimulated somatostatin secretion.
Methods
Animals and cell culture All procedures were carried out in
accordance with the principles of laboratory animal care as
well as requirements of local and national authorities. NMRI
mice were killed by cervical dislocation and pancreatic islets
were isolated as previously described [3]. Islets were
cultured in RPMI 1640 medium supplemented with fatty
acid-free BSA (1%, wt/vol.) alone or with 0.5 mmol/l of
oleate or palmitate at 4.5 and 15 mmol/l glucose. The
NEFA stock solutions were prepared as described previ-
ously; the estimated unbound NEFA concentration was
26 nmol/l for palmitate and 47 nmol/l for oleate and was
estimated by the stepwise equilibrium method [3]. The data
reported here were obtained in islets treated identically to
those previously used for the analysis of the long-term
effects of glucose and NEFA on insulin secretion [3].
Hormone release measurements Groups of ten to 12 size-
matched islets were pre-incubated for 30 min in 1 ml Krebs
Ringer solution, containing (in mmol/l): 140 NaCl, 3.6 KCl,
2N a H C O 3, 0.5 NaH2PO4,0 . 5M g S O 4, 5 HEPES (pH 7.4
with NaOH), 2.6 CaCl2, 1 glucose and 1% BSA (wt/vol.).
Islets were then incubated in 1 ml of the same solution
containing 1 or 20 mmol/l glucose for 1 h. Islet hormone
content was determined after extraction with acidic ethanol.
Glucagon and somatostatin were determined using in-house
radioimmunoassays [4]. All chemicals were of analytical
grade and purchased from Sigma (Gillingham, UK).
Electron microscopy Ultrastructural analysis was per-
formed by electron microscopy as described previously [3].
Statistical analyses Data or transformed data were analysed
by one-way ANOVA and a least significant difference
multiple comparison test using SPSS software (SPSS,
Chicago, IL, USA).
Results
Glucagon Glucagon content was reduced by ∼20%
by palmitate or oleate when the islets were cultured
at 4.5 mmol/l glucose. Culture in the presence of
15 mmol/l glucose for 72 h increased islet glucagon content
by ∼50% relative to that observed following culture at
4.5 mmol/l glucose. The latter increase was antagonised by
inclusionofoleate orpalmitateintheculturemedium (Fig.1a).
The effects of oleate and palmitate on glucagon
secretion, whether in the presence of low (4.5 mmol/l) or
high (15 mmol/l) glucose, were identical and resulted in
stimulation of basal (at 1 mmol/l glucose) glucagon
secretion and complete loss of the inhibition that is
normally produced by glucose at 20 mmol/l. Interestingly,
culture at high glucose alone also abolished the inhibitory
effect of 20 mmol/l glucose, whereas secretion at 1 mmol/l
was unaffected (Fig. 1b).
Somatostatin No significant differences in somatostatin con-
tents were observed (Fig. 1c). Basal somatostatin secretion
was marginally increased both by culture at high glucose and
by the NEFA when applied at the lower glucose concentra-
tion (Fig. 1d ) .H o w e v e r ,g l u c o s e - s t i m u l a t e ds o m a t o s t a t i n
release was reduced by oleate and palmitate exposure; the
Fig. 1 Glucagon (a) and somatostatin (c) content in islets treated with
low (4.5 mmol/l) or high (15 mmol/l) glucose, in the presence or
absence of palmitate (P) or oleate (O). Data are presented as mean±SEM
offourexperiments. *p<0.05 for control islets at 15 mmol/l glucose vs all
other groups. Glucagon (b) and somatostatin (d) hormone secretion in
islets treated as indicated (a, c). Secretion was measured at 1 (black) and
2 0m m o l / l( g r e y )g l u c o s ed u r i n g1hi n c u b a t i o nf o l l o w i n gt h e7 2hc u l t u r e
at the indicated conditions. Data are presented as mean±SEM of four
experiments. *p<0.05 (at least) for comparisons with secretion measured
at 1 mmol/l glucose in the respective groups;
†p<0.05 (at least) for
comparison with secretion measured at 1 mmol/l glucose in islets cultured
at 4.5 mmol/l glucose;
‡p<0.05 (at least) for comparison of secretion
measured in the presence of 20 mmol/l glucose in islets cultured for 72 h at
4.5 mmol/l glucose;
§p<0.05 (at least) for comparison of secretion
measured in the presence of 20 mmol/l glucose in islets cultured for 72 h at
15 mmol/l glucose
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concentration during the culture period. There were no
statistically significant differences between the release rates
measured in the presence of 20 mmol/l glucose in islets
cultured at low or high glucose for any of the conditions
(Fig. 1d).
Electron microscopy Figure 2 shows electron micrographs
of islets cultured at 15 mmol/l glucose alone (Fig. 2a) and
when the culture medium was supplemented with palmitate
(Fig. 2b, c) or oleate (Fig. 2d). The alpha, beta and delta
cells were identified on the basis of the appearance of the
secretory granules. All islet cells appeared structurally
intact with no obvious signs of apoptosis. However,
exposure to oleate resulted in the appearance of translucent
lipid droplets similar to those previously described in Ins1
cells exposed to lipids [5]. In oleate-treated islets, 80% of
the beta cells (16 out of 20 cells), 9% of the alpha cells (one
out of 11 cells) and 8% of the delta cells (one out of 12
cells) contained lipid droplets. Following exposure to
palmitate, 92% of the beta cells (12 out of 13 cells)
contained crescent-like structures similar to those previous-
ly documented in Ins1 cells and believed to represent
tripalmitin deposition [5]; beta cells exposed to palmitate
did not contain lipid droplets of the type seen in oleate-
treated cells. No signs of lipid deposition were seen in non-
beta cells exposed to palmitate (three delta cells and ten
alpha cells were analysed).
Discussion
The adverse effects of long-term exposure to NEFA on
glucose-stimulated insulin secretion are well established
[2]. Much less is known about the consequences of a
chronic elevation of NEFA on the release of somatostatin
and glucagon. Here we demonstrate a dichotomy in the
effects of long-term exposure to NEFA. Thus, whereas
glucose-induced release of somatostatin, like that of insulin,
was reduced following 72 h exposure to the NEFA,
glucagon secretion was stimulated. In addition, the ability
of high glucose concentrations to suppress glucagon release
was abolished.
Following long-term exposure to the lipids, 80% to 90% of
beta cells displayed signs of lipid deposition inside the cells in
the form of lipid droplets and crescent-like structures,
respectively. Many of the crescent-like structures were (at least
partially) membrane-delimited, whereas the lipid droplets
observed following exposure to oleate were without boundary
membrane. The crescent-like structures might represent
expansions of the endoplasmic reticulum [5], possibly an
early sign of endoplasmic reticulum stress. Importantly, the
ultrastructure of the non-beta cells was much less affected by
long-term exposure to lipids, with the crescent-like structures
being confined to the beta cells. Thus, alpha and delta cells
would be expected to be less sensitive to lipids than beta cells
and this may contribute to the hormonal abnormalities
associated with obesity and diabetes.
Fig. 2 Electron micrograph through mouse islets incubated for
72 h in 15 mmol/l glucose alone (a) and in 15 mmol/l glucose with
0.5 mmol/l palmitate (b, c) or 0.5 mmol/l oleate (d). Alpha, beta and
delta cells are indicated. The presence of crescent-like structures in
palmitate-treated cells (b, c) and oleate-induced lipid droplets are
indicated by white arrows. The cell borders are indicated schemati-
cally by the dashed white lines. Micrographs and data presented in the
text are representative of four to seven islets obtained from two
different mice. Scale bar, 1 μm
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been regarded to be similar to that of insulin secretion.
Recently, however, it has become apparent that the
mechanisms controlling glucose-induced insulin and so-
matostatin secretion are quite different. Thus, somatostatin
release is highly dependent on Ca
2+-induced Ca
2+ release
(CICR) [6]. It is possible that long-term exposure to NEFA
might interfere with CICR and thus lower glucose-induced
somatostatin secretion.
There have been few reports on the long-term effects of
glucose and NEFA on glucagon secretion. Rat islets
exposed for 24 h to 0.6 mmol/l palmitate have been
reported to have 50% lower glucagon content than controls
[7]. It has been argued that this effect is the result of
insufficient biosynthesis in the face of higher secretion [8].
This may explain why glucagon content decreased follow-
ing long-term exposure to NEFA (30–40%), a condition
that led to stimulation of glucagon secretion. Conversely,
the observed oversecretion of glucagon in islets cultured in
the presence of NEFA cannot be accounted for by increased
islet glucagon content. Thus, it seems justifiable to
conclude that this stimulation results from a genuine effect
on intracellular signalling within the alpha cell.
Glucagonsecretionhasbeenproposedtobeunderparacrine
control. According to this concept, the reduction of insulin
(and other factors co-released with insulin such as Zn
2+)a n d
somatostatin may underlie the hypersecretion of glucagon.
However, it should be noted that culture at high glucose alone
has only a marginal effect on glucose-induced insulin and
somatostatin secretion and yet the suppressor effect of high
glucose on glucagon secretion is abolished. Thus, the
observed stimulation of glucagon release cannot be explained
in terms of defective paracrine regulation and rather suggests
that the defect occurs within the alpha cell itself. In this
context it may be of relevance that NEFA metabolites like
palmitoyl-CoA activates KATP-channels [9]. Recent data
indicate that low concentrations of the KATP-channel opener
diazoxide stimulate glucagon secretion and antagonise the
inhibitory effect of glucose [10]. If enough acyl-CoAs are
generated in alpha cells to exert a diazoxide-like effect, it may
contribute to the loss of glucose regulation of glucagon
secretion. The long-term effects of NEFA are rather similar to
the acute actions previously reported [1]. Under acute
conditions, application of NEFA did in fact exert a
diazoxide-like effect on alpha cell [Ca
2+]i and lead to the
reappearance of [Ca
2+]i oscillations in cells where they had
been suppressed by high glucose.
In mouse pancreatic beta cells, long-term exposure to
lipids does not result in any obvious functional impairment
that explains the strong reduction of glucose-induced
insulin secretion. Thus, metabolism, electrical activity and
intracellular [Ca
2+]i signalling all proceed as well as or
better than in control cells and much of the effect on
glucose induced insulin secretion is independent of cyto-
toxicity [3]. Instead, we proposed that lipids may interfere
with insulin release at the level of fusion pore expansion
(i.e. distal to the fusion of the granules with the plasma
membrane), resulting in failure of the fusion pore to expand
sufficiently to allow macromolecules like insulin to exit.
The fact that glucagon secretion is enhanced rather than
inhibited following lipid exposure suggests that there is
some cell-specificity of the effect.
Oversecretionofglucagonandinsufficientreleaseofinsulin
are part of the aetiology of type 2 diabetes. The data presented
here illustrate that the two defects may be interrelated. Thus,
mild disturbances of insulin and glucagon secretion and/or a
slight elevation of plasma NEFA levels can be envisaged to
result in a vicious cycle of progressively impaired glucose
regulation of insulin and glucagon release that eventually
culminates in glucose intolerance and overt diabetes.
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